Author name: Leonardo Arias

Next-generation automation is closing the gap between curative science and real-world demand, enabling faster development, global consistency and broader patient access to CAR T therapies.

Industry leaders are focused on the resilience of key starting material supply and the knock-on effects of automation in the new year.

In a year that saw advisory committees placed under a particularly bright microscope at the FDA, the agency held fewer meetings than usual and agreed with its advisors only 57% of the time, Jefferies reported.

Only a handful of the top pharmas have signed Most Favored Nation drug pricing deals with the White House, while smaller biotechs continue to hang in limbo.

States received an average of $200 million to expand rural care access. Texas received the most money, while New Jersey received the least.

A Maine district court temporarily enjoined the pilot, which was set to take effect on Jan. 1, from kicking in. Still, the controversial payment experiment isn’t dead in the water, as the Trump administration quickly appealed the ruling.

The extension, released shortly before the flexibilities were set to expire at the end of 2025, gives regulators more time to finish permanent policies, the agencies said.

Executives at companies innovating a range of new robotic surgery platforms shared their progress and challenges in MedTech Dive’s series of profiles.

Stanley Bergman has worked at Henry Schein for 45 years, more than 35 of which he spent as CEO, and was due to retire at the end of 2025.

The expanded tax credits are officially dead after lawmakers failed to secure an extension before the end-of-year deadline. There’s still a chance, though a small one, that they could come back in 2026.